4//SEC Filing
Bernard Gordon R 4
Accession 0001209191-19-047327
CIK 0001087294other
Filed
Aug 22, 8:00 PM ET
Accepted
Aug 23, 4:56 PM ET
Size
12.2 KB
Accession
0001209191-19-047327
Insider Transaction Report
Form 4
Bernard Gordon R
Senior Vice President
Transactions
- Sale
Common Stock
2019-08-15$5.75/sh−78$449→ 41,862 total - Sale
Common Stock
2019-08-19$5.45/sh−1,000$5,450→ 40,362 total - Sale
Common Stock
2019-08-16$5.71/sh−500$2,855→ 41,362 total - Sale
Common Stock
2019-08-20$5.41/sh−2,631$14,234→ 37,731 total - Sale
Common Stock
2019-08-21$5.45/sh−2,100$11,445→ 35,631 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.38, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.69, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.38, inclusive.
Documents
Issuer
CUMBERLAND PHARMACEUTICALS INC
CIK 0001087294
Entity typeother
Related Parties
1- filerCIK 0001470015
Filing Metadata
- Form type
- 4
- Filed
- Aug 22, 8:00 PM ET
- Accepted
- Aug 23, 4:56 PM ET
- Size
- 12.2 KB